Note: Supplemental materials are not guaranteed with Rental or Used book purchases.
- ISBN: 9780192869227 | 0192869221
- Cover: Hardcover
- Copyright: 1/16/2024
Raffaele De Caterina, Director, Chair and School of Specialization in Diseases of the Cardiovascular System, Cardiovascular Division, Pisa University Hospital, and University of Pisa, Pisa, Italy,David Moliterno, Professor of Medicine in the Department of Internal Medicine, Division of Cardiovascular Medicine, Gill Heart and Vascular Institute, University of Kentucky, Lexington, Kentucky, USA,Steen Kristensen, Consultant Cardiologist and Head of the Cardiovascular Research Centre, Department of Cardiology, Aarhus University Hospital Skejby, Denmark
Raffaele De Caterina is Professor of Cardiology at the University of Pisa, and Director, University Cardiology Division, at Pisa University Hospital. He is also Scientific Advisor for the "G. Monasterio" Foundation, Pisa, Italy. He has been Vice-President of the European Society of Cardiology (2008-2010) and President (2009-2013) of the International Society on Nutrigenetics/Nutrigenomics. He is the past-Editor-in-Chief of the journal Vascular Pharmacology, curent Executive Editor of European Heart Journal, and author of >600 peer-reviewed manuscripts. Major research interests: Cardiovascular Pharmacology, Atrial Fibrillation, Coronary Artery Disease, Cardiovascular Thrombosis, Nutrigenetics and Nutrigenomics.
David J. Moliterno, MD (FESC, FACC, FSCAI, FAHA) is a Professor at the University of Kentucky. He was an attending cardiologist at the Cleveland Clinic for 10 years before joining the University of Kentucky, where he was chief of cardiovascular medicine and subsequently chair of internal medicine. Dr. Moliterno has been a visiting professor or lecturer in more than 30 countries. He is the author of over 400 publications and editor of 8 textbooks. He has been the primary author of publications in BMJ, Circulation, EHJ, JACC, JAMA, Lancet, and NEJM. He is currently the Editor-in-Chief for the JACC: Cardiovascular Interventions and serves on the advisory board of the US FDA. As a clinical researcher, Dr. Moliterno has been a leader in numerous multinational investigational studies. Collectively, these studies have involved over $1 billion in clinical trial research. His primary interests involve acute coronary syndromes, antithrombotic therapies, and interventional cardiology.
Steen Dalby Kristensen is a professor and interventional cardiologist at Aarhus University Hospital, Denmark. Scientific/clinical interests: Thrombosis and anti-thrombotic treatment. Coronary artery disease and acute cardiac care. Percutaneous coronary interventions. Author of more than 365 scientific papers and 17 book chapters. Editor of 5 textbooks. Editor of European Heart Journal, Thrombosis and Haemostasis and European Heart Journal: Acute Cardiovascular Care. Invited speaker in more than 40 different countries. Supervisor of 15 PhD students. Chair of international research committees for evaluation of scientific applications in Germany and Spain. Evaluator of grants in Sweden, Norway, Italy, Germany, Spain, Finland and Denmark. Has been ESC Vice-president, ESC secretary/treasurer and leader of several key ESC initiatives, ESC committees and working groups. Past President of the Danish Society of Cardiology
1. Introduction, Raffaele De Caterina, David J. Moliterno, and Steen Dalby Kristensen
Section 1: Pathophysiology of thrombosis
2. Arterial thrombosis: Pathophysiological background, Lina Badimon and Gemma Vilahur
3. Venous thrombosis and thromboembolism: Pathophysiological background, Marcello Di Nisio, Nicola Potere, Harry R. Buller, and Nick van Es
4. Thrombosis & thromboembolism in atrial fibrillation: Pathophysiological background, Peter Calvert, Nicola Tidbury, and Gregory Y. H. Lip
5. Thrombosis on foreign surfaces and devices, Tobias Geisler
Section 2: Clinical pharmacology of antithrombotic drugs
6. Aspirin, Carlo Patrono and Bianca Rocca
7. Platelet P2Y12 inhibitors, Manan Pareek and Deepak L. Bhatt
8. Dipyridamole, cilostazol, GP IIb/IIIa inhibitors, and PAR-1 antagonists, Luis Ortega-Paz and Dominick Angiolillo
9. Heparins, fondaparinux, hirudin, bivalirudin, argatroban and danaparoid, Renske Olie and Hugo ten Cate
10. Vitamin K antagonists, Freek W.A. Verheugt and Marc Brouwer
11. Dabigatran, Alex Benz and Stefan Hohnloser
12. Oral factor Xa (FXa) inhibitors, Lars C. Wallentin, Agneta Siegbahn, Peter Svensson, and Hakan Wallen
13. Forthcoming oral factor XIa and FXIIa inhibitors, James C. Fredenburgh and Jeffrey I. Weitz
14. Thrombolytic therapy and ancillary antithrombotic therapies, Peter R Sinnaeve and Frans Van de Werf
Section 3: Therapeutic strategies
15. Antithrombotic strategies in primary cardiovascular prevention, Raffaele De Caterina, Paul M Ridker, and Erica Michelotti
16. Antithrombotic strategies in patients undergoing elective percutaneous coronary interventions and in chronic coronary syndromes without interventions, Antonio Greco and Davide Capodanno
17. Antithrombotic therapy in ST-elevation acute myocardial infarction and non-ST elevation acute coronary syndromes, William A. E. Parker, Raffaele De Caterina, David J. Moliterno, Steen Dalby Kristensen and Robert F. Storey
18. Anti-thrombotic therapy for patients with prosthetic valves and during structural percutaneous interventions, Naoki Misumida, Mohamad Alkhouli, and David J. Moliterno
19. Antithrombotic therapies in ischaemic stroke, Hans Christoph Diener, Graeme J. Hankey, and John W. Eikelboom
20. Antithrombotic therapy in patients with patent foramen ovale (PFO), PFO closure, left ventricular mural thrombus, atrial thrombus, and catheter-related thrombosis, Jens Erik Nielsen-Kudsk, Kasper Korsholm, Asger Andersen, and Erik Lerkevang Grove
21. Atrial fibrillation: current and forthcoming antithrombotic therapies, Raffaele De Caterina and Rossella Marcucci
22. Venous thromboembolism: prophylaxis and treatment, Chaozer Er, Walter Ageno, and Ander Cohen
23. Biomarker-based risk stratification in cardiovascular disease, Lars C. Wallentin, Ziad Hijazi, Gorav Bartra, and Johan Lindbäck
Section 4: Special situations
24. Antithrombotic therapies in inherited or acquired thrombophilia, Vittorio Pengo and Gentian Denas
25. Prevention and treatment of bleeding related to antithrombotic drug treatment, Roxana Mehran, Alessandro Spirito, George Dangas, and David Cao
26. Management of patients treated with antithrombotic drugs undergoing surgery, Michael Maeng, Steen Dalby Kristensen, and Jolanta M. Siller-Matula
27. Antithrombotic therapy in patients with atrial fibrillation and recent coronary stenting, with or without an acute coronary syndrome, Alexander C Fanaroff, Renato D Lopes, John H Alexander
28. Prevention and treatment of venous and arterial thrombosis in patients with specific conditions: diabetes, renal insufficiency, thrombophilia and pregnancy, Stefan Agewall, Vanessa Roldán, and Francisco Marín
29. Antithrombotic agents and drug-drug interactions, Steven P. Dunn, Craig J. Beavers, and David J. Moliterno
30. Personalised antithrombotic therapy: Measuring individual variation and monitoring, Jur ten Berg, Dirk Sibbning, Wout W.A. van den Broek, and Konstantinos D. Rizas
31. Drug development, clinical trials, and regulatory requirements, Serge Korjian, Yazan Daaboul, and C. Michael Gibson
What is included with this book?
The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.